A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

NCT07585266 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Neoplasms

Interventions

DRUG: Velzatinib
DRUG: Imatinib

Sponsor

GlaxoSmithKline